Clinical remission was achieved at 6 months after starting VDZ.<h4>Conclusion</h4>VDZ might represent a valid option to treat patients with BD who are non-responsive to standard treatments or anti-TNFα agents, particularly, those cases with intestinal involvement. The gene discussed is TNF; the disease is Behcet disease.